These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 22176529)

  • 21. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
    Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
    Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
    Matsuura K; Makino H; Ogawa N
    Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Full and partial peroxisome proliferation-activated receptor-γ agonists, but not δ agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.
    Sadeghian M; Marinova-Mutafchieva L; Broom L; Davis JB; Virley D; Medhurst AD; Dexter DT
    J Neuroimmunol; 2012 May; 246(1-2):69-77. PubMed ID: 22498097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profiling changes in gait dynamics resulting from progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced nigrostriatal lesioning.
    Goldberg NR; Hampton T; McCue S; Kale A; Meshul CK
    J Neurosci Res; 2011 Oct; 89(10):1698-706. PubMed ID: 21748776
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
    Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
    J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. M30, a brain permeable multitarget neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models.
    Youdim MB
    Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S151-4. PubMed ID: 22166418
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reversal of dopaminergic degeneration in a parkinsonian rat following micrografting of human bone marrow-derived neural progenitors.
    Glavaski-Joksimovic A; Virag T; Chang QA; West NC; Mangatu TA; McGrogan MP; Dugich-Djordjevic M; Bohn MC
    Cell Transplant; 2009; 18(7):801-14. PubMed ID: 19796495
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast growth factor 20 is protective towards dopaminergic neurons in vivo in a paracrine manner.
    Boshoff EL; Fletcher EJR; Duty S
    Neuropharmacology; 2018 Jul; 137():156-163. PubMed ID: 29698669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 1,25-Dihydroxyvitamin D3 administration to 6-hydroxydopamine-lesioned rats increases glial cell line-derived neurotrophic factor and partially restores tyrosine hydroxylase expression in substantia nigra and striatum.
    Sanchez B; Relova JL; Gallego R; Ben-Batalla I; Perez-Fernandez R
    J Neurosci Res; 2009 Feb; 87(3):723-32. PubMed ID: 18816795
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exogenous l-DOPA induce no dopamine immuno-reactivity in striatal astroglias and microglias of adult rats with extensive nigro-striatal dopaminergic denervation.
    Maeda T; Nagata K; Yoshida Y
    Neurosci Lett; 2008 Mar; 433(3):255-8. PubMed ID: 18255227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial effects of intraventricularly administered BMP-7 following a striatal 6-hydroxydopamine lesion.
    Zuch CL; David D; Ujhelyi L; Hudson JL; Gerhardt GA; Kaplan PL; Bickford PC
    Brain Res; 2004 Jun; 1010(1-2):10-6. PubMed ID: 15126112
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.
    Knyihár-Csillik E; Chadaide Z; Mihály A; Krisztin-Péva B; Fenyo R; Vécsei L
    Acta Neuropathol; 2006 Aug; 112(2):127-37. PubMed ID: 16788821
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Catalpol attenuates MPTP induced neuronal degeneration of nigral-striatal dopaminergic pathway in mice through elevating glial cell derived neurotrophic factor in striatum.
    Xu G; Xiong Z; Yong Y; Wang Z; Ke Z; Xia Z; Hu Y
    Neuroscience; 2010 Apr; 167(1):174-84. PubMed ID: 20123001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biochemical and immunocytochemical changes induced by intrastriatal 6-hydroxydopamine injection in the rat nigrostriatal dopamine neuron system: evidence for cell death in the substantia nigra.
    Ichitani Y; Okamura H; Nakahara D; Nagatsu I; Ibata Y
    Exp Neurol; 1994 Dec; 130(2):269-78. PubMed ID: 7867756
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ALCAR Exerts Neuroprotective and Pro-Neurogenic Effects by Inhibition of Glial Activation and Oxidative Stress via Activation of the Wnt/β-Catenin Signaling in Parkinsonian Rats.
    Singh S; Mishra A; Shukla S
    Mol Neurobiol; 2016 Sep; 53(7):4286-301. PubMed ID: 26223802
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease.
    Kim S; Moon M; Park S
    J Endocrinol; 2009 Sep; 202(3):431-9. PubMed ID: 19570816
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulation of GAP-43 protein and mRNA in nigrostriatal dopaminergic neurons after the partial destruction of dopaminergic terminals with intrastriatal 6-hydroxydopamine.
    Iwata SI; Nomoto M; Fukuda T
    Synapse; 2001 Jan; 39(1):16-22. PubMed ID: 11071705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Potential neuroprotective effect of low dose whole-body gamma-irradiation against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic toxicity in C57 mice.
    Liang Y; Li S; Zou Q; Su B
    Neurosci Lett; 2006 Jun; 400(3):213-7. PubMed ID: 16540245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.